CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 192 enrolled
Drug / intervention
Selective Serotonin Reuptake Inhibitor (SSRI)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01811147
NCT01811147Phase 4Completed
CompareCT.gov

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

The Cleveland Clinic·interventional·Posted Mar 14, 2013·Updated Dec 2, 2019

In Brief

A Phase 4 clinical trial evaluating Selective Serotonin Reuptake Inhibitor (SSRI) for Bipolar Disorder and Major Depression. Completed, enrolled 192 participants across 1 site.

Detailed Summary

The purpose of the study is to find out what parts of the brain have increased or decreased activity and connectivity in individuals who have bipolar disorder, major depression, or no history of mood disorder. Another purpose of this study is to use MRI images to determine which young adults with major depression may be at greater risk for developing mild or more severe symptoms of mania which suggests a diagnosis of bipolar disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder, Major Depression
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 14, 2013
Enrollment StartNov 1, 2011
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 13.3 years ago

Interventions

Selective Serotonin Reuptake Inhibitor (SSRI)drug

Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.